@article{57c218db73214ca7be915aab4359cf76,
title = "Supporting the next generation of scientists to lead cancer immunology research",
abstract = "Recent success in the use of immunotherapy for a broad range of cancers has propelled the field of cancer immunology to the forefront of cancer research. As more and more young investigators join the community of cancer immunologists, the Arthur L. Irving Family Foundation Cancer Immunology Symposium provided a platform to bring this expanding and vibrant community together and support the development of the future leaders in the field. This commentary outlines the lessons that emerged from the inaugural symposium highlighting the areas of scientific and career development that are essential for professional growth in the field of cancer immunology and beyond. Leading scientists and clinicians in the field provided their experience on the topics of scientific trajectory, career trajectory, publishing, fundraising, leadership, mentoring, and collaboration. Herein, we provide a conceptual and practical framework for career development to the broader scientific community.",
author = "Elise Alspach and Chow, {Ryan D.} and Shadmehr Demehri and Guerriero, {Jennifer L.} and Shashi Gujar and Hartmann, {Felix J.} and Helmink, {Beth A.} and Hudson, {William H.} and Ho, {Won Jin} and Leyuan Ma and Maier, {Barbara B.} and Maltez, {Vivien I.} and Miller, {Brian C.} and Moran, {Amy E.} and Parry, {Erin M.} and Pillai, {Padmini S.} and Sarwish Rafiq and Miguel Reina-Campos and Rosato, {Pamela C.} and Rudqvist, {Nils Petter} and Ruhland, {Megan K.} and Idit Sagiv-Barfi and {Das Sahu}, Avinash and Samstein, {Robert M.} and Sch{\"u}rch, {Christian M.} and Sen, {Debattama R.} and Thommen, {Daniela S.} and Yochai Wolf and Roberta Zappasodi",
note = "Funding Information: J.L. Guerriero reports grants and personal fees from GlaxoSmithKline and Array BioPharma, and grants from Eli Lilly outside the submitted work. W.J. Ho reports other support from Rodeo/Amgen, grants from Sanofi, and personal fees from Exelixis outside the submitted work. B.C. Miller reports grants from NCI during the conduct of the study, as well as personal fees from Rheos Medicines, Inc. outside the submitted work. E.M. Parry reports grants from Doris Duke Charitable Foundation and ASCO Conquer Cancer Foundation outside the submitted work. M. Reina-Campos reports personal fees from Pandion Therapeutics, a subsidiary of Merck, outside the submitted work. C.M. Schu€rch reports grants and other support from Enable Medicine, Inc. outside the submitted work, as well as a patent for anti-CD70 combination therapy issued and a patent for method for predicting patient response to immunotherapy pending. R. Zappasodi reports grants from Parker Institute for Cancer Immunotherapy and NCI during the conduct of the study; other support from Leap Therapeutics and iTEOS Therapeutics outside the submitted work; and a patent for WO2015184099A1 licensed, a patent for US20170081409A1 licensed, a patent for WO2018106864A1 licensed, and a patent for 62/582,416 pending. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2021 The Authors; Published by the American Association for Cancer Research.",
year = "2021",
month = nov,
doi = "10.1158/2326-6066.CIR-21-0519",
language = "English",
volume = "9",
pages = "1245--1251",
journal = "Cancer immunology research",
issn = "2326-6066",
number = "11",
}